SCHEMBL6733067

SCHEMBL6733067

CCCS(=O)(=O)N(Cc1cccnc1)c1ccc(Oc2ccc(Oc3cccs3)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 19/20 0.67
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6727566 0.95 GRM2 (0.74) GRM2
SCHEMBL6735686 0.89 GRM2 (0.61) GRM2MMP2MMP9
SCHEMBL6732757 0.87 GRM2 (0.89) GRM2
SCHEMBL6733269 0.85 GRM2 (0.69) GRM2
SCHEMBL6728309 0.85 GRM2 (0.74) GRM2
SCHEMBL6732595 0.84 GRM2 (0.80) GRM2
SCHEMBL6738353 0.83 GRM2 (0.54) GRM2MMP2MMP9
SCHEMBL6727529 0.82 GRM2 (0.69) GRM2
SCHEMBL6733619 0.82 GRM2 (0.79) GRM2
SCHEMBL6731895 0.82 GRM2 (0.70) GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6800651-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-10-05 US claimed
US-20040006114-A1 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-01-08 US claimed
EP-1255735-A2 PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2002-11-13 EP claimed
WO-2001056990-A2 PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2001-08-09 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006114-A1 Potentiators of glutamate receptors GRM1, GRIN1, GRM2 GRM2 3/4885MMP2 4427/4885MMP9 4367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.